Longitudinal Women's Health Studies Shaping Current Clinical Practice

For nearly a century, clinicians based most of what they knew about postmenopausal women on inference rather than direct data from women. The 1977 FDA guidelines urged excluding women of childbearing from early-phase trials, an approach that hardened across decades and created a gap that widened as National Institutes of Health funding in women's health stayed below 11 percent. This narrative look at current findings for menopausal hormone therapy situates the funding gap alongside the wider research clinicians still use. Most participants were young adults, with an upper cutoff of 65 years, producing major gaps in women's health. Cardiovascular risk, hormone therapy, and related concerns: clinicians based their assumptions largely on male physiology, applied outward. The gap was no footnote. It was the entire framework, and filling it in required three coordinated research efforts, launched a generation apart.

Structure of the WHI, SWAN, and Nurses' Health Studies to fill that gap

The WHI, started by the NIH in 1991, is still the biggest women's health prevention study ever conducted. Instead of one trial, it combined a clinical trial with an observational study plus a prevention study promoting healthful behaviors broadly. Dr. Bernadine Healy, the NIH's first female director, oversaw its creation with funding big enough to support that scope. The study had $625 million to work with, targeting what kills or leaves postmenopausal women: cardiovascular disease, osteoporosis, and cancer, breast plus colorectal.

SWAN followed another path. It helped shape STRAW+10, the staging system for reproductive aging, Staging of Reproductive Aging Workshop+10.

Of the group, the Nurses' Health Studies span the most years. The original cohort launched in 1976, with a cohort following in 1989 and an open-enrollment cohort recruiting since 2010; combined, they encompass hundreds of thousands of participants. These studies used distinct ways to ask one question: swapping assumption for data from the women it affected. Over 161,000 women joined at 40 clinical sites in a randomized clinical trial enrolling tens of thousands of postmenopausal women ages 50–79 from 1993 to 1998. SWAN started in 1994, recruiting its baseline cohort during 1996–97 to follow women traversing midlife into adulthood.

The WHI's 2002 hormone therapy findings versus what clinicians heard

The most consequential finding from this field came out July 2002, with the finding itself holding up. The problem lay in its transmission. The WHI's account of combined estrogen-plus-progestin therapy got the main finding right, but it reached clinical practice in a cruder shape than the data supported and triggered a much more sweeping retreat from hormone therapy than warranted.

The trial found that combined CEE-MPA therapy raised the likelihood of heart disease, stroke, and clots, alongside breast cancer. This was a genuine finding, and it earned the notice it received. But that left out part of the story, and the nuance never reached doctors' offices. By 2005, Prescriptions for hormone therapy had dropped sharply in most places; some estimates say the findings prevented many breast cancer and cardiovascular illnesses while saving billions in United States health care spending. Up to that point, it was a real win for health.

The retreat continued past where the findings ended. For most women who have Menopause symptoms, they disrupt everyday life, but over 80 percent don't ask for treatment, leaving a gap tied to decades of under-recognition after overcorrection. Manson and coauthors published in JAMA on the WHI data, showing outcomes shift with a woman's years and cardiovascular risk, so this variability rather than sweeping caution should shape how women 50 or beyond reach hormone therapy decisions alongside clinicians. The 2024 review, offering a 20-year look at trials run from 1993 to 1998, underscored why postmenopausal women should leave one-size-fits-all care and called for women and physicians to reach shared, individualized decisions around symptoms, preferences, lifestyle, disease risks, and other health factors. That difference didn't show up in the 2002 headlines. Clinical practice absorbed guidance that was blunt, while the data had produced a much more conditional picture.

The timing hypothesis's reframing of cardiovascular risk and hormone therapy

The correction that followed left the 2002 findings standing. It polished them. Looking at the WHI data more closely showed that cardiovascular outcomes from hormone therapy shift a lot based on timing, it's the gap between beginning therapy and menopause onset that matters, and the original headlines never allowed for that.

The timing hypothesis: starting hormone therapy before 60 or inside 10 years of menopause could confer cardiovascular gains, or at least neutrality, whereas initiating past 65 raises coronary and stroke odds. So the clinical focus shifted from deciding to prescribe hormone therapy at all to choosing who gets it and when to start. Another WHI analysis published in 2025 by JAMA Internal Medicine, with Rossouw and colleagues in charge, examined cardiovascular outcomes according to vasomotor symptom patterns, giving the timing hypothesis more texture but not settling the question outright.

Still, the WHI investigators behind this data are flagging its limits themselves. They say a prospective clinical trial for the timing hypothesis is not feasible, and its observational data relies on self-selected long-term hormone users, a group prone to survivor effects, healthy-user bias, and confounding. The timing hypothesis has clinical value. Measured against the field's own bar, it isn't confirmed. The data on dementia and cognitive decline is far clearer, with no study showing menopausal hormone therapy protects against either. The caution here has held up rather than softened.

SWAN's unique contribution of studying the transition rather than the destination

Looking back at menopause and tracking it in real time are distinct research paths, and SWAN picked the latter. Tracking women across stages before menopause, peri, and postmenopausal periods, instead of sampling them afterward, let SWAN isolate which health shifts came from ovarian aging and which came from age. That separation feels abstract until you weigh the stakes: cardiovascular disease claims more women's lives than anything else, with SWAN's data confirming that menopause transition itself, beyond chronological years, accelerates vascular risk in ways cardiology guidelines now reflect. That finding has started feeding into the risk-stratification models behind cardiology guidelines.

STRAW+10 also bears SWAN's fingerprints, the staging system clinicians rely on to locate a woman along the timeline of reproductive aging. That staging system exists as it does only because a study focused on the transition itself.

SWAN's latest line of work is about dementia and merits more than a quick note. That study has a clear reason: cardiovascular health drops faster for many women during the menopause transition, and it is itself a modifiable risk tied to Alzheimer's disease plus other dementias. The study is in its sixth funding phase, with one in-person visit, Visit 17, for the whole cohort, adding new measures on cognition, sleep, physical activity, cardiovascular health, social functioning, urogenital health, and sexual health. In 2025, a SWAN-based analysis published in Alzheimer's & Dementia (DOI: 10.1002/alz70860_103069) examined how cardiovascular health at each menopausal stage, scored with Life's Essential 8 metrics, ties to later subjective cognitive outcomes.

The Nurses' Health Studies and Decades of Lifestyle and Dietary Causation

WHI's clinical trial and SWAN's transition-tracking could not address one issue: how do dietary and lifestyle choices from youth and midlife shape post-menopause disease risk decades on? The Nurses' Health Studies were designed to answer that question. A questionnaire-based cohort tracked over decades can trace exposures, sleep, physical activity, and dietary patterns that no trial could ethically randomize or any transition study observe.

The findings show the same pattern, and sometimes echo and sharpen what WHI saw in a calcium and vitamin D trial of its own. For postmenopausal women, Calcium plus vitamin D supplementation seems to drop the cancer death risk by 7 percent, while nudging up the odds of fatal heart disease. Separately, WHI's data showed low-fat diets lower ovarian cancer risk, and that result belongs to WHI, not NHS. NHS data shows that too much or not enough nightly sleep increases the risk of cognitive decline.

The three-cohort setup from 1976, 1989, and 2010 matters most because it lets researchers weigh women whose early-life exposures and medical care were quite different, a payoff that keeps getting better as each cohort ages. It completes the triptych: WHI tested interventions, SWAN tracked one biological transition, and NHS traces origins across decades of ordinary choices.

Regulatory and funding decisions translating decades of data into, or away from, clinical practice

All of this work has to go somewhere, and today it's ending up in two spots pulling opposite ways at the same time. Three decades of clinical guidelines were built on the same longitudinal data, which now finds itself caught between a regulatory liberalization and a funding threat to the infrastructure that generated it.

The FDA rescinded 22-year-old black-box warnings for hormone therapy in November 2025, downstream of accumulated WHI plus SWAN data moving into regulatory practice, marking its liberalization. certaintynews.com and patientcareonline.com describe the change as grounded in newer evidence and a sharper view of who benefits from hormone therapy and when. Clinicians, using the timing hypothesis, fit hormone therapy to each patient's case and timing, not one class-wide caution for all. The Menopause Society launched a big program to teach a new cohort of practitioners about menopause and the realities of midlife women's health.

When it comes to funding, the picture is much less clear. In April 2025, Robert F was heading Health and Human Services. Jr said he would terminate WHI site contracts in California, Ohio, New York, plus North Carolina before September arrived. If carried out as planned, that move would have stopped data collection involving tens of thousands of women, ages 78 to 108, surviving members from the study's founding group. Outcry reversed it quickly, yet the moment exposed the fragility of long-term women's health systems. bcvoices.org reported that government workers were asked not to use terms such as "female," "women" or "underrepresented," though caution did not apply to "male" or "men," affecting how this work gets funded later.

Some questions remain unresolved. Fred Hutchinson Cancer Center confirmed the WHI's clinical coordinating center will run until January 2026, leaving later funding unresolved. The WHI extension study aimed to gather health data on 52,068 volunteers until 2026, focused on aging, cardiovascular problems, and heart disease, but regional center funding had been terminated in September 2025, leaving the coordinating center's path after January unsettled. Nobody has decided yet if the data collection will go on after January.